Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | DBH | P09172 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259355 | 0.82 | MAPT (0.39) | PTGDR2MAPTP2RX7DBH | |
| SCHEMBL4977919 | 0.80 | KMT2A (0.40) | KMT2APTGDR2POLBCYP3A4CYP2C19 | |
| SCHEMBL4976840 | 0.77 | POLB (0.37) | MAPTCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL4979616 | 0.75 | KMT2A (0.37) | KMT2AMAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL2484248 | 0.74 | PTGDR2 (0.64) | KMT2APTGDR2MAPTPOLB | |
| SCHEMBL4974510 | 0.74 | CNR1 (0.49) | KMT2AMAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL4979970 | 0.73 | AKR1B1 (0.41) | KMT2ACYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL4979166 | 0.73 | CYP1A2 (0.39) | KMT2AMAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL4979426 | 0.73 | CNR1 (0.51) | KMT2AMAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL2486352 | 0.72 | PTGDR2 (0.62) | PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984374-A1 | USE OF SPIRO Ý IMIDAZOLIDINE-4, 3'-INDOLE¨2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | AstraZeneca AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091946-A1 | USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |